iCRT-5

• CAT Number: M079375
• CAS Number: 18623-44-4
• Molecular Formula: C16H17NO5S2
• Molecular Weight: 367.44
• Purity: ≥95%
• Synonyms: 4-[(5Z)-5-[(3,4-dimethoxyphenyl)methylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid
• InChI: InChI=1S/C16H17NO5S2/c1-21-11-6-5-10(8-12(11)22-2)9-13-15(20)17(16(23)24-13)7-3-4-14(18)19/h5-6,8-9H,3-4,7H2,1-2H3,(H,18,19)/b13-9-
• InChIKey: IJWKSBPTJQMUHJ-LCYFTJDESA-N
• SMILES: COC1=C(C=C(C=C1)C=C2C(=O)N(C(=S)S2)CCCC(=O)O)OC

iCRT-5 (Cat No.: M079375) is a small-molecule inhibitor that targets the Wnt/β-catenin signaling pathway, a key regulator of cell proliferation, differentiation, and tumorigenesis. It disrupts the interaction between β-catenin and T-cell factor/lymphoid enhancer factor (TCF/LEF) transcription factors, thereby suppressing β-catenin–mediated gene expression. iCRT-5 is widely used in cancer research to study Wnt-driven oncogenesis and as a chemical probe for evaluating therapeutic strategies that modulate aberrant Wnt signaling. It provides a valuable tool for investigating stem cell biology, oncology, and regenerative medicine.

Reference

[1]. Käfer R, et, al. Inhibitors of β-catenin affect the immuno-phenotype and functions of dendritic cells in an inhibitor-specific manner. Int Immunopharmacol. 2016 Mar;32:118-124.
[Content Brief]

[2]. Narayanan BA, et, al. Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma. Anticancer Res. 2012 Nov;32(11):4697-707.
[Content Brief]